Provided by Tiger Fintech (Singapore) Pte. Ltd.

MannKind

5.05
-0.0150-0.30%
Volume:1.88M
Turnover:9.51M
Market Cap:1.55B
PE:51.54
High:5.14
Open:5.03
Low:5.01
Close:5.06
52wk High:7.07
52wk Low:3.38
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.75
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0979
EPS(LYR):0.1005
ROE:32.74%
ROA:9.95%
PB:-34.77
PE(LYR):50.18

Loading ...

MannKind EVP Technical Operations Sanjay R. Singh Reports Sale of Common Shares

Reuters
·
Nov 15

MannKind to Present at the Jefferies Global Healthcare Conference

GlobeNewswire
·
Nov 12

MannKind Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Nov 11

Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating

MT Newswires Live
·
Nov 11

MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation

TIPRANKS
·
Nov 11

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Tower Semiconductor, GlobalFoundries

Reuters
·
Nov 11

H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news

TIPRANKS
·
Nov 11

MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities

TIPRANKS
·
Nov 11

MannKind Corp : Leerink Partners Cuts Target Price to $7 From $9

THOMSON REUTERS
·
Nov 10

MannKind Shares Fall 3.3% After Co to Discontinue Late-Stage Trial of Lung Disease Treatment

THOMSON REUTERS
·
Nov 10

MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease

MT Newswires Live
·
Nov 10

MannKind Shares Down After Lung Disease Drug Trial Discontinued

Dow Jones
·
Nov 10

MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine

TIPRANKS
·
Nov 10

MannKind Shares Fall 5.7% Premarket After Co to Discontinue Phase 3 Clinical Trial of Lung Disease Treatment

THOMSON REUTERS
·
Nov 10

Stock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial

Stock Track
·
Nov 10

Stock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial

Stock Track
·
Nov 10

MannKind Corp - Mnkd-102 Development Remains Under Consideration

THOMSON REUTERS
·
Nov 10

MannKind: No Conversions Observed in Phase 3 ICON-1 Trial, Prompting Concerns Regarding Likelihood of Achieving Study's Key Primary Endpoint

THOMSON REUTERS
·
Nov 10

MannKind Provides Update on Phase 3 ICON-1 Trial of Nebulized Clofazimine for Ntm Lung Disease

THOMSON REUTERS
·
Nov 10

MannKind Corp - Independent Dsmb Agrees to Discontinue Trial Due to Futility

THOMSON REUTERS
·
Nov 10